Shionogi Past Earnings Performance
Past criteria checks 2/6
Shionogi has been growing earnings at an average annual rate of 9%, while the Pharmaceuticals industry saw earnings growing at 10.4% annually. Revenues have been growing at an average rate of 6% per year. Shionogi's return on equity is 12.6%, and it has net margins of 36.3%.
Key information
9.0%
Earnings growth rate
10.5%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | 6.0% |
| Return on equity | 12.6% |
| Net Margin | 36.3% |
| Next Earnings Update | 13 May 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Shionogi makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 425,157 | 154,458 | 94,611 | 100,217 |
| 30 Sep 23 | 506,446 | 218,294 | 94,637 | 100,868 |
| 30 Jun 23 | 464,156 | 192,805 | 94,381 | 104,859 |
| 31 Mar 23 | 426,684 | 184,965 | 93,637 | 102,392 |
| 31 Dec 22 | 453,859 | 200,914 | 92,021 | 99,585 |
| 30 Sep 22 | 340,832 | 118,318 | 90,146 | 93,550 |
| 30 Jun 22 | 338,012 | 116,669 | 88,574 | 80,797 |
| 31 Mar 22 | 335,138 | 114,185 | 87,877 | 72,996 |
| 31 Dec 21 | 292,384 | 96,785 | 88,697 | 63,234 |
| 30 Sep 21 | 293,810 | 115,608 | 89,478 | 57,570 |
| 30 Jun 21 | 294,740 | 122,560 | 89,271 | 56,812 |
| 31 Mar 21 | 297,177 | 111,858 | 88,387 | 54,249 |
| 31 Dec 20 | 304,276 | 117,422 | 44,764 | 87,183 |
| 30 Sep 20 | 320,946 | 119,958 | 60,143 | 72,803 |
| 30 Jun 20 | 325,548 | 119,311 | 75,136 | 60,115 |
| 31 Mar 20 | 333,371 | 122,193 | 91,802 | 47,949 |
| 31 Dec 19 | 351,993 | 129,259 | 87,810 | 68,325 |
| 30 Sep 19 | 356,395 | 126,479 | 90,621 | 68,325 |
| 30 Jun 19 | 354,422 | 125,285 | 90,546 | 68,325 |
| 31 Mar 19 | 363,721 | 132,759 | 101,978 | 68,325 |
| 31 Dec 18 | 346,547 | 123,483 | 106,516 | 59,945 |
| 30 Sep 18 | 340,698 | 116,426 | 105,021 | 59,945 |
| 30 Jun 18 | 358,168 | 124,748 | 105,440 | 59,945 |
| 31 Mar 18 | 344,667 | 108,866 | 95,592 | 59,945 |
| 31 Dec 17 | 345,719 | 96,065 | 100,385 | 59,907 |
| 30 Sep 17 | 355,961 | 103,017 | 97,665 | 59,907 |
| 30 Jun 17 | 340,755 | 87,353 | 96,835 | 59,907 |
| 31 Mar 17 | 338,890 | 83,879 | 93,027 | 59,907 |
| 31 Dec 16 | 340,583 | 92,559 | 97,889 | 49,787 |
| 30 Sep 16 | 326,795 | 76,499 | 98,233 | 49,787 |
| 30 Jun 16 | 319,268 | 69,566 | 96,047 | 49,787 |
| 31 Mar 16 | 309,973 | 66,687 | 94,021 | 49,787 |
| 31 Dec 15 | 299,645 | 59,468 | 92,424 | 48,870 |
| 30 Sep 15 | 282,428 | 55,736 | 91,484 | 48,870 |
| 30 Jun 15 | 275,117 | 43,395 | 90,997 | 48,870 |
| 31 Mar 15 | 273,991 | 44,060 | 92,566 | 48,870 |
| 31 Dec 14 | 271,887 | 30,857 | 91,525 | 51,924 |
| 30 Sep 14 | 280,844 | 30,136 | 92,211 | 51,924 |
| 30 Jun 14 | 285,189 | 41,307 | 94,344 | 51,924 |
| 31 Mar 14 | 289,717 | 41,831 | 96,243 | 51,924 |
| 31 Dec 13 | 289,559 | 75,622 | 94,190 | 53,021 |
| 30 Sep 13 | 284,296 | 73,269 | 94,464 | 53,021 |
| 30 Jun 13 | 282,345 | 70,663 | 94,170 | 53,021 |
Quality Earnings: SH0 has high quality earnings.
Growing Profit Margin: SH0's current net profit margins (36.3%) are lower than last year (44.3%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: SH0's earnings have grown by 9% per year over the past 5 years.
Accelerating Growth: SH0's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: SH0 had negative earnings growth (-23.1%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (3.8%).
Return on Equity
High ROE: SH0's Return on Equity (12.6%) is considered low.